O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors
Raj N, Klimstra D, Horvat N, Zhang L, Chou J, Capanu M, Basturk O, Gian R, Allen P, Reidy-Lagunes D. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas 2017, 46: 758-763. PMID: 28609363, PMCID: PMC5509357, DOI: 10.1097/mpa.0000000000000842.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic Agents, AlkylatingBiomarkers, TumorCell DifferentiationChildDacarbazineDatabases, FactualDisease ProgressionDNA MethylationDNA Modification MethylasesDNA Repair EnzymesDrug Resistance, NeoplasmFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeuroendocrine TumorsPancreatic NeoplasmsPharmacogeneticsPromoter Regions, GeneticSequence Analysis, DNATemozolomideTime FactorsTreatment OutcomeTumor Suppressor ProteinsYoung AdultConceptsPancreatic neuroendocrine tumorsProgression of diseaseWD-panNETsStable diseasePartial responseNeuroendocrine tumorsAlkylating agentsAlkylating agent therapyResponse Evaluation CriteriaResistance to alkylating agentsMGMT deficiencyAgent therapyEvaluation CriteriaSolid tumorsMGMTTumorGlioblastoma multiformePanNETsPatientsDiseaseDecreased activityDNA methyltransferasesAgentsRECISTStatus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply